308 related articles for article (PubMed ID: 21624418)
1. Marked enhancement of the immune response to BioThrax® (Anthrax Vaccine Adsorbed) by the TLR9 agonist CPG 7909 in healthy volunteers.
Rynkiewicz D; Rathkopf M; Sim I; Waytes AT; Hopkins RJ; Giri L; DeMuria D; Ransom J; Quinn J; Nabors GS; Nielsen CJ
Vaccine; 2011 Aug; 29(37):6313-20. PubMed ID: 21624418
[TBL] [Abstract][Full Text] [Related]
2. Increased potency of BioThrax anthrax vaccine with the addition of the C-class CpG oligonucleotide adjuvant CPG 10109.
Gu M; Hine PM; James Jackson W; Giri L; Nabors GS
Vaccine; 2007 Jan; 25(3):526-34. PubMed ID: 16973247
[TBL] [Abstract][Full Text] [Related]
3. Randomized, double-blind, active-controlled study evaluating the safety and immunogenicity of three vaccination schedules and two dose levels of AV7909 vaccine for anthrax post-exposure prophylaxis in healthy adults.
Hopkins RJ; Kalsi G; Montalvo-Lugo VM; Sharma M; Wu Y; Muse DD; Sheldon EA; Hampel FC; Lemiale L
Vaccine; 2016 Apr; 34(18):2096-105. PubMed ID: 26979136
[TBL] [Abstract][Full Text] [Related]
4. Randomized, double-blind, placebo-controlled, safety and immunogenicity study of 4 formulations of Anthrax Vaccine Adsorbed plus CPG 7909 (AV7909) in healthy adult volunteers.
Hopkins RJ; Daczkowski NF; Kaptur PE; Muse D; Sheldon E; LaForce C; Sari S; Rudge TL; Bernton E
Vaccine; 2013 Jun; 31(30):3051-8. PubMed ID: 23701746
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: a randomized, double-blinded, controlled, multicenter trial.
Gorse GJ; Keitel W; Keyserling H; Taylor DN; Lock M; Alves K; Kenner J; Deans L; Gurwith M
Vaccine; 2006 Aug; 24(33-34):5950-9. PubMed ID: 16797805
[TBL] [Abstract][Full Text] [Related]
6. Phase 3 trial evaluating the immunogenicity and safety of a three-dose BioThrax® regimen for post-exposure prophylaxis in healthy adults.
Hopkins RJ; Howard C; Hunter-Stitt E; Kaptur PE; Pleune B; Muse D; Sheldon E; Davis M; Strout C; Vert-Wong K
Vaccine; 2014 Apr; 32(19):2217-24. PubMed ID: 24613523
[TBL] [Abstract][Full Text] [Related]
7. A plant based protective antigen [PA(dIV)] vaccine expressed in chloroplasts demonstrates protective immunity in mice against anthrax.
Gorantala J; Grover S; Goel D; Rahi A; Jayadev Magani SK; Chandra S; Bhatnagar R
Vaccine; 2011 Jun; 29(27):4521-33. PubMed ID: 21504775
[TBL] [Abstract][Full Text] [Related]
8. Anthrax vaccine adsorbed: further evidence supporting continuing the vaccination series rather than restarting the series when doses are delayed.
Pittman PR; Cavicchia MA; Kingsbury JL; Johnson NA; Barrera-Oro JG; Schmader T; Korman L; Quinn X; Ranadive M
Vaccine; 2014 Sep; 32(39):5131-9. PubMed ID: 24837771
[TBL] [Abstract][Full Text] [Related]
9. An intranasal vaccine targeting both the Bacillus anthracis toxin and bacterium provides protection against aerosol spore challenge in rabbits.
Wimer-Mackin S; Hinchcliffe M; Petrie CR; Warwood SJ; Tino WT; Williams MS; Stenz JP; Cheff A; Richardson C
Vaccine; 2006 May; 24(18):3953-63. PubMed ID: 16530302
[TBL] [Abstract][Full Text] [Related]
10. Effect of delayed anthrax vaccine dose on Bacillus anthracis protective antigen IgG response and lethal toxin neutralization activity.
Pittman PR; Fisher D; Quinn X; Schmader T; Barrera-Oro JG
Vaccine; 2013 Oct; 31(44):5009-14. PubMed ID: 24026013
[TBL] [Abstract][Full Text] [Related]
11. Increased long-term immunity to Bacillus anthracis protective antigen in mice immunized with a CIA06B-adjuvanted anthrax vaccine.
Wui SR; Han JE; Kim YH; Rhie GE; Lee NG
Arch Pharm Res; 2013 Apr; 36(4):464-71. PubMed ID: 23440578
[TBL] [Abstract][Full Text] [Related]
12. A combination of the TLR4 agonist CIA05 and alum promotes the immune responses to Bacillus anthracis protective antigen in mice.
Wui SR; Kim HK; Han JE; Kim JM; Kim YH; Chun JH; Cho YJ; Lee NG
Int Immunopharmacol; 2011 Sep; 11(9):1195-204. PubMed ID: 21492746
[TBL] [Abstract][Full Text] [Related]
13. Enhanced early innate and T cell-mediated responses in subjects immunized with Anthrax Vaccine Adsorbed Plus CPG 7909 (AV7909).
Minang JT; Inglefield JR; Harris AM; Lathey JL; Alleva DG; Sweeney DL; Hopkins RJ; Lacy MJ; Bernton EW
Vaccine; 2014 Nov; 32(50):6847-54. PubMed ID: 24530403
[TBL] [Abstract][Full Text] [Related]
14. Trimethyl Chitosan Nanoparticles Encapsulated Protective Antigen Protects the Mice Against Anthrax.
Malik A; Gupta M; Mani R; Gogoi H; Bhatnagar R
Front Immunol; 2018; 9():562. PubMed ID: 29616046
[TBL] [Abstract][Full Text] [Related]
15. Poly-gamma-d-glutamic acid and protective antigen conjugate vaccines induce functional antibodies against the protective antigen and capsule of Bacillus anthracis in guinea-pigs and rabbits.
Lee DY; Chun JH; Ha HJ; Park J; Kim BS; Oh HB; Rhie GE
FEMS Immunol Med Microbiol; 2009 Nov; 57(2):165-72. PubMed ID: 19732139
[TBL] [Abstract][Full Text] [Related]
16. Validation and long term performance characteristics of a quantitative enzyme linked immunosorbent assay (ELISA) for human anti-PA IgG.
Semenova VA; Schiffer J; Steward-Clark E; Soroka S; Schmidt DS; Brawner MM; Lyde F; Thompson R; Brown N; Foster L; Fox S; Patel N; Freeman AE; Quinn CP
J Immunol Methods; 2012 Feb; 376(1-2):97-107. PubMed ID: 22197974
[TBL] [Abstract][Full Text] [Related]
17. Mouse model characterisation for anthrax vaccine development: comparison of one inbred and one outbred mouse strain.
Flick-Smith HC; Waters EL; Walker NJ; Miller J; Stagg AJ; Green M; Williamson ED
Microb Pathog; 2005 Jan; 38(1):33-40. PubMed ID: 15652293
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of early immune response-survival relationship in cynomolgus macaques after Anthrax Vaccine Adsorbed vaccination and Bacillus anthracis spore challenge.
Sivko GS; Stark GV; Tordoff KP; Taylor KL; Glaze E; VanRaden M; Schiffer JM; Hewitt JA; Quinn CP; Nuzum EO
Vaccine; 2016 Dec; 34(51):6518-6528. PubMed ID: 27155494
[TBL] [Abstract][Full Text] [Related]
19. Epitope-focused peptide immunogens in human use adjuvants protect rabbits from experimental inhalation anthrax.
Oscherwitz J; Feldman D; Yu F; Cease KB
Vaccine; 2015 Jan; 33(3):430-6. PubMed ID: 25454087
[TBL] [Abstract][Full Text] [Related]
20. Phase 1 study of a recombinant mutant protective antigen of Bacillus anthracis.
Bellanti JA; Lin FY; Chu C; Shiloach J; Leppla SH; Benavides GA; Karpas A; Moayeri M; Guo C; Robbins JB; Schneerson R
Clin Vaccine Immunol; 2012 Feb; 19(2):140-5. PubMed ID: 22190398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]